Pharmaceutical intelligence for Casper Pharma LLC with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

RegulatoryJune 30, 2026

FDA Approves Tioprinin for Treatment of Cystinosis

The FDA has approved Tioprinin under NDA212927 for the treatment of cystinosis.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(1)

RegulatoryJune 30, 2026

FDA Approves Tioprinin for Treatment of Cystinosis

The FDA has approved Tioprinin under NDA212927 for the treatment of cystinosis.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Tioprinin →

Therapeutic areas

Cystinosis →

Rare Diseases →

Indications

Rare Diseases →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.